Thus, we established for the first time a non-invasive, plasma-based assay for the quantification of circulating S100A4 transcripts in blood of colon, rectal, and gastric cancer patients, that allows clinical application routinely for diagnosis, prognosis and for monitoring treatment success [73]. This evidence concerns the gene S100A4 and gastric cancer.